Medical/Pharmaceuticals
RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name
The "B" marker is removed from the Company's stock short name
YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
2023-06-05 21:17
3405
Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with symptomatic heart failure who have iron deficiency ST. GALLEN, Switzerland, June 5, 2023 /PRNewswire/ -- CSL...
2023-06-05 21:00
2875
Waters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing
News Summary: * Integration of Sartorius' process scale multi-column chromatography with Waters' process analytical technology to provide robust analytical data for downstream biomanufacturing of mAbs, recombinant proteins, vaccines, and other biologics. * Integrated solution to deliver vita...
2023-06-05 20:00
2586
Prenetics Announces First Quarter 2023 Financial Results
HONG KONG, June 5, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision oncology company, today announced financial results for the first quarter endedMarch 31, 2023, along with recent business updates. First Quarter 2023 Fi...
2023-06-05 19:20
3199
Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", Stock Code: 2257.HK, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the in...
2023-06-05 19:12
2703
ISCT 2023: Late-breaking SCG101 Data Show 100% HBsAg+ Hepatocyte Eradication and 74.5% HCC Tumour Reduction With Single Dose HBsAg-specific TCR-T Cell Therapy
SINGAPORE, June 5, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, presented late-breaking data from its first-in-class autologous HBsAg-specific T-Cell receptor-engi...
2023-06-05 10:28
2272
Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-06-05 08:00
4607
Turn Biotechnologies Founder to be Featured Speaker at Japanese Society of Anti-Aging Medicine Meeting
MOUNTAIN VIEW, Calif., June 5, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, announced that its co-founderVittorio Sebastiano will be a featured participant at one of the world's longest-running conf...
2023-06-05 08:00
2123
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, June 4, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-06-04 08:36
3952
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-06-03 07:59
22027
Anti- Ageing and Reproductive Medical Giants to Gather in Hong Kong, Dragon's Medical Leads Chinese Medical Development
Hong Kong, June 2, 2023 /PRNewswire/ -- Dragon's Medical
2023-06-02 23:02
5240
Transcenta Holding Limited (6628.HK) to Hold 2023 ASCO Business Update call Conference.
SUZHOU, China, June 2, 2023 /PRNewswire/ -- The management team of Transcenta Holding Limited (06628.HK) will attend the 2023 ASCO Business Update Call conference onJune 7, 2023. Transcenta is a clinical stage biopharmaceutical company with fully integrated capabilities in the discovery, research...
2023-06-02 19:14
4935
Latest Updates of 9 Viva's Portfolio Companies
HONG KONG, June 2, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...
2023-06-02 18:51
3182
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research
SAN DIEGO and SAN JOSE, Calif., June 2, 2023 /PRNewswire/ -- Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics' NGS platforms. The territory is worldwide, and the field is oncology and cancer...
2023-06-02 18:00
3178
Sunway Medical Centre Velocity Awarded by Frost & Sullivan for Leading the Malaysian Hospital Industry with Holistic Medical Care and Pioneering Technologies
Sunway Medical Centre Velocity in Kuala Lumpur delivers a wide range of medical specialties supported by highly trained professionals and advanced technologies. SAN ANTONIO, June 2, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the Malaysian hospital industry and, based on its finding...
2023-06-02 11:46
2708
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
ROCKVILLE, Md. and SUZHOU, China, June 2, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-06-02 08:00
5651
CAMH study confirms ongoing brain inflammation associated with long COVID
Researchers using advanced brain imaging are first to find increase in protein marker of inflammation in illness affecting 200 million globally TORONTO, June 2, 2023 /PRNewswire/ -- A new CAMH study published in the journalJAMA Psychiatry found elevated levels of inflammation in the brain of pa...
2023-06-02 04:07
2598
EVERSANA Forms Strategic Alliance with China Resource Pharmaceutical Commercial Group to Bring New Novel Treatments to Patients Globally
BEIJING, June 2, 2023 /PRNewswire/ -- EVERSANA®, a leading provider of commercialization services to the global life sciences industry, today announced that it has established a strategic alliance with the China Resources Pharmaceutical Commercial Group, a leading pharmaceutical distribution ent...
2023-06-02 00:10
2803
Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
HONG KONG, Germantown, Md. and Suzhou, China, June 2, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today...
2023-06-02 00:06
6697
AtomVie Global Radiopharma raises over $90M to Complete its New Facility Buildout
HAMILTON, ON, June 1, 2023 /PRNewswire/ -- AtomVie Global Radiopharma Inc. (AtomVie), a global-leading CDMO for the GMP manufacturing and worldwide distribution of radiopharmaceuticals, today announced the closing of its Tranche 2 Series A financing led by its current investor, Avego Management, ...
2023-06-01 21:00
1778
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2928
